FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014619641> ?p ?o ?g. }

• W2014619641 endingPage "222" @default.
• W2014619641 startingPage "214" @default.
• W2014619641 abstract "Erectile dysfunction (ED) is often associated with a cluster of risk factors for coronary artery disease and reduced endothelial function. Acute and chronic administration of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, improves endothelial function in patients with ED. Tadalafil (TAD) is a new PDE5 inhibitor with a long half life that allows alternate day administration. Aim of the study was to evaluate whether chronic therapy (4 weeks) with TAD improves endothelial function in patients with increased cardiovascular risk and whether this effect is sustained after discontinuation of therapy.We randomized 32 patients with increased cardiovascular risk to receive either TAD 20 mg on alternate days or matching placebo (PLB) for 4 weeks. Patients underwent evaluation of brachial artery flow-mediated dilation (FMD), nitrite/nitrate and endothelin-1 plasma levels at baseline, at the end of treatment period and after two-weeks follow-up.At 4 weeks, FMD was significantly improved by TAD (from 4.2+/-3.2 to 9.3+/-3.7%, p<0.01 vs. baseline), but was not modified by PLB (from 4.1+/-2.8 to 4.0+/-3.4%, p=NS). At 6 weeks the benefit in FMD was sustained in patients that received TAD (9.1+/-3.9% vs. 4.2+/-3.2%, p=0.01 vs. baseline; 9.1+/-3.9% vs. 9.3+/-3.7%, vs. 4 weeks, p=NS) while no changes in FMD were observed in patients randomized to PLB. Also, compared to baseline, a net increase in nitrite/nitrate levels (38.2+/-12.3 vs. 52.6+/-11.7 and 51.1+/-3.1, p<0.05) and a decrease in endothelin-1 levels (3.3+/-0.9 vs. 2.9.+/-0.7 and 2.9+/-0.9, p<0.05) was found both at four and six-weeks after TAD; these changes were inversely correlated as shown by regression analysis (adjusted R2=0.81, p<0.0001).Chronic therapy with TAD improves endothelial function in patients with increased cardiovascular risk regardless their degree of ED. The benefit of this therapy is sustained for at least two weeks after the discontinuation of therapy. Larger studies are needed in order to assess the possible clinical implications of chronic therapy with TAD." @default.
• W2014619641 created "2016-06-24" @default.
• W2014619641 creator A5059966253 @default.
• W2014619641 creator A5063960004 @default.
• W2014619641 creator A5068884647 @default.
• W2014619641 creator A5078111994 @default.
• W2014619641 creator A5087977641 @default.
• W2014619641 creator A5089438091 @default.
• W2014619641 date "2005-02-01" @default.
• W2014619641 modified "2023-10-09" @default.
• W2014619641 title "Chronic Treatment with Tadalafil Improves Endothelial Function in Men with Increased Cardiovascular Risk" @default.
• W2014619641 cites W1494463289 @default.
• W2014619641 cites W1607525380 @default.
• W2014619641 cites W1640899337 @default.
• W2014619641 cites W1919106200 @default.
• W2014619641 cites W1928263104 @default.
• W2014619641 cites W1963704175 @default.
• W2014619641 cites W1975319833 @default.
• W2014619641 cites W1987876724 @default.
• W2014619641 cites W1996468763 @default.
• W2014619641 cites W2009550279 @default.
• W2014619641 cites W2020004023 @default.
• W2014619641 cites W2023364581 @default.
• W2014619641 cites W2042239656 @default.
• W2014619641 cites W2044810125 @default.
• W2014619641 cites W2057116025 @default.
• W2014619641 cites W2073394949 @default.
• W2014619641 cites W2078714359 @default.
• W2014619641 cites W2090141049 @default.
• W2014619641 cites W2094151199 @default.
• W2014619641 cites W2097450392 @default.
• W2014619641 cites W2099719839 @default.
• W2014619641 cites W2113446450 @default.
• W2014619641 cites W2118285681 @default.
• W2014619641 cites W2121247582 @default.
• W2014619641 cites W2121939064 @default.
• W2014619641 cites W2132288985 @default.
• W2014619641 cites W2137570167 @default.
• W2014619641 cites W2138798974 @default.
• W2014619641 cites W2153625446 @default.
• W2014619641 cites W2158368439 @default.
• W2014619641 cites W2160314451 @default.
• W2014619641 cites W2164161035 @default.
• W2014619641 cites W2171104973 @default.
• W2014619641 cites W2171236476 @default.
• W2014619641 cites W2297358297 @default.
• W2014619641 cites W2324841714 @default.
• W2014619641 cites W2341645956 @default.
• W2014619641 cites W2517252201 @default.
• W2014619641 cites W4249818967 @default.
• W2014619641 cites W4298963798 @default.
• W2014619641 doi "https://doi.org/10.1016/j.eururo.2004.10.002" @default.
• W2014619641 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16145432" @default.
• W2014619641 hasPublicationYear "2005" @default.
• W2014619641 type Work @default.
• W2014619641 sameAs 2014619641 @default.
• W2014619641 citedByCount "238" @default.
• W2014619641 countsByYear W20146196412012 @default.
• W2014619641 countsByYear W20146196412013 @default.
• W2014619641 countsByYear W20146196412014 @default.
• W2014619641 countsByYear W20146196412015 @default.
• W2014619641 countsByYear W20146196412016 @default.
• W2014619641 countsByYear W20146196412017 @default.
• W2014619641 countsByYear W20146196412018 @default.
• W2014619641 countsByYear W20146196412019 @default.
• W2014619641 countsByYear W20146196412020 @default.
• W2014619641 countsByYear W20146196412021 @default.
• W2014619641 countsByYear W20146196412022 @default.
• W2014619641 countsByYear W20146196412023 @default.
• W2014619641 crossrefType "journal-article" @default.
• W2014619641 hasAuthorship W2014619641A5059966253 @default.
• W2014619641 hasAuthorship W2014619641A5063960004 @default.
• W2014619641 hasAuthorship W2014619641A5068884647 @default.
• W2014619641 hasAuthorship W2014619641A5078111994 @default.
• W2014619641 hasAuthorship W2014619641A5087977641 @default.
• W2014619641 hasAuthorship W2014619641A5089438091 @default.
• W2014619641 hasConcept C126322002 @default.
• W2014619641 hasConcept C142724271 @default.
• W2014619641 hasConcept C164705383 @default.
• W2014619641 hasConcept C168563851 @default.
• W2014619641 hasConcept C204787440 @default.
• W2014619641 hasConcept C27081682 @default.
• W2014619641 hasConcept C2776768464 @default.
• W2014619641 hasConcept C2777604165 @default.
• W2014619641 hasConcept C2778213512 @default.
• W2014619641 hasConcept C2778715236 @default.
• W2014619641 hasConcept C2779929075 @default.
• W2014619641 hasConcept C2780816001 @default.
• W2014619641 hasConcept C2780972559 @default.
• W2014619641 hasConcept C71924100 @default.
• W2014619641 hasConcept C84393581 @default.
• W2014619641 hasConceptScore W2014619641C126322002 @default.
• W2014619641 hasConceptScore W2014619641C142724271 @default.
• W2014619641 hasConceptScore W2014619641C164705383 @default.
• W2014619641 hasConceptScore W2014619641C168563851 @default.
• W2014619641 hasConceptScore W2014619641C204787440 @default.
• W2014619641 hasConceptScore W2014619641C27081682 @default.
• W2014619641 hasConceptScore W2014619641C2776768464 @default.

• next